143例少见类型宫颈癌患者HPV感染情况分析

Abstract
Figure/Table
References (20)
Related Citation (14)

Download: PDF (631 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To provide more evidence for the estimation of potential impact of HPV vaccine, by analyzing the distribution of HPV genotypes in unusual types of cervical cancer. Methods From September 2014 to September 2017, in West China Second Hospital of Sichuan University, unusual types of cervical cancer were collected, HPV genotyping was done by use of PCR and Luminex fluorescence technique. Relative contribution of HPV types in ICCs was expressed as the percentages of type-specifc cases among HPV-positive cases. Multiple infections were incorporated into single infection using the method of proportional weighting attribution (PWA). Results In the study, 143 invasive cervical cancer cases were included, and 130 (90.91%) cases were positive for HPV DNA, among them, 60 (46.15%) cases were adenocarcinoma (ADC), 46 (35.38%) cases were adenosquamous cell carcinoma (ADSCC), 8 (6.15%) cases were neuroendocrine carcinoma (NECA) and 16 (12.31%) cases were mixed type, 109 (83.84%) cases were present as single infections and 21 (16.15%) cases were present as multiple infections. HPV types 16 and 18 were the major types in each histological group. The PWA of HPV 16/18 to ADC, ADSCC, NECA and mixed type were 85.88%, 93.39%, 100.00% and 83.32%, respectively. Conclusion HPV 16 and 18 infections are predominant in these unusual types of cervical cancer. The 9-valent HPV vaccine has some improvement for prevention of these unusual types of cervical cancer.

Key words： Genotype Uterine cervical cancer Adenocarcinoma Adenosquamous cell carcinoma Neuroendocrine carcinoma Vaccine

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIAO Xin ZOU Juan HUANG Anliang YU Na SUN Liang▲

Cite this article:

LIAO Xin ZOU Juan HUANG Anliang YU Na SUN Liang▲. HPV genotyping in 143 cases of unusual types carcinoma of the uterine cervix[J]. 中国医药导报, 2018, 15(9): 85-88.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I9/85

[1] Ferlay J，Soerjomataram I，Dikshit R，et al. Cancer incidence and mortality worldwide：sources，methods and major patterns in GLOBOCAN 2012 [J]. Int J Cancer，2015， 136（5）：E359-E386.
[2] Plummer M，de Martel C，Vignat J，et al. Global burden of cancers attributable to infections in 2012：a synthetic analysis [J]. Lancet Glob Health，2016，4（9）：e609-e616.
[3] Mu?觡oz N，Bosch FX，de Sanjosé S，et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer [J]. N Engl J Med，2003，348（6）：518-527.
[4] Bansal A，Singh MP，Rai B. Human papillomavirus-associated cancers：a growing global problem [J]. Int J Appl Basic Med Res，2016，6（2）：84-89.
[5] FUTURE Ⅱ Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions [J]. N Engl J Med，2007，356（19）：1915-1927.
[6] Joura EA，Giuliano AR，Iversen OE，et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women [J]. N Engl J Med，2015，372（19）：711-723.
[7] Kurman RJ，Carcangiu ML，Herrington CS，et al. WHO Classification of Tumors of Female Reproductive Organs [M]. Lyon：IARC Press，2014：183-198.
[8] Stoler MH，Srodon M，Baber GB，et al. The frequency and biology of multiple HPV infection in vulvar neoplasia. USCAP Abstract 954 [J]. Mod Pathol，2005，18：205A.
[9] Insinga RP，Liaw KL，Johnson LG，et al. A systematic review of the prevalence and attribution of human papillomavirus types among cervical，vaginal，and vulvar precancers and cancers in the United States [J]. Cancer Epidemiol Biomarkers Prev，2008，17（7）：1611-1622.
[10] Bzhalava D，Guan P，Franceschi S，et al. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types [J]. Virology，2013，445（1）：224-231.
[11] Bray F，Loos AH，McCarron P，et al.Trends in cervical squamous cell carcinoma incidence in 13 European countries：changing risk and the effects of screening [J]. Cancer Epidemiol Biomarkers Prev，2005，14 （3）：677-686.
[12] Oh CM，Jung KW，Won YJ，et al. Trends in the incidence of in situ and invasive cervical cancer by age group and histological type in Korea from 1993 to 2009 [J]. PLoS One，2013，8（8）：e72012.
[13] Li S，Zhu H. Twelve cases of neuroendocrine carcinomas of the uterine cervix：cytology，histopathology and discussion of their histogenesis [J]. Acta Cytol，2013，57（1）：54-60.
[14] Li N，Franceschi S，Howell-Jones R，et al. Human papillomavirus type distribution in 30，848 invasive cervical cancers worldwide：Variation by geographical region，histological type and year of publication [J]. Int J Cancer，2011，128（4）：927-935.
[15] de Sanjose S，Quint WG，Alemany L，et al. Human papillomavirus genotype attribution in invasive cervical cancer：a retrospective cross-sectional worldwide study [J]. Lancet Oncol，2010，11（11）：1048-1056.
[16] Pirog EC，Lloveras B，Molijn A，et al. HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma，a worldwide analysis of 760 cases [J]. Mod Pathol，2014，27（12）：1559-1567.
[17] Castle PE，Amanda PA，Mark HS. A systematic review and meta-analysis on the attribution of human papillomavirus （HPV） in neuroendocrine cancers of the cervix[J]. Gynecol Oncol ，2018，148（2）：422-429.
[18] Lee SA，Kang D，Seo S，et al. Multiple HPV infection in cervical cancer screened by HPV DNA chip [J]. Cancer Lett，2003，198（2）：187-192.
[19] Tran LT，Tran LT，Bui TC，et al. Risk factors for high-risk and multiple human papillomavirus infections among women in Ho Chi Minh City，Vietnam：a cross-sectional study [J]. BMC Womens Health，2015，15（1）：172-180.
[20] Spinillo A，Bello BD，Alberizzi P，et al. Clustering patterns of human papillomavirus genotypes in multiple infections [J]. Virus Res，2009，142（1-2）：154-159.